Nomad Power Secures $6.57M Note from Streeterville Capital — All Assets Pledged
NMAD sits 66% above its 52-week low of $2.36.
Summary
Nomad Power Solutions raised $6.0 million in gross proceeds through a $6.57 million secured note from Streeterville Capital, pledging all company assets and subsidiary guarantees. The 12-month note carries a 9% rate, a $540K OID, and a mandatory 25% prepayment on any future financing.
Key Events · Financing and Capital Events · NMAD
-
$6.57M Secured Note Issued
On September 28, 2026, Nomad Power Solutions entered a Note Purchase Agreement with Streeterville Capital, issuing a $6.57 million secured promissory note for $6.0 million in gross proceeds after a $540,000 OID and $30,000 in transaction expenses.
-
All Assets Pledged as Collateral
The note is secured by a first-position security interest in substantially all company assets, including equity interests in subsidiaries, accounts receivable, equipment, and intellectual property. Subsidiaries Lixte Biotechnology, Nomad Transportable Power Systems, and Liora Technologies Europe provided guarantees.
-
Mandatory 25% Prepayment on Future Financing
The company must immediately prepay 25% of any future fundraising or financing proceeds (including warrant exercises, ATM financing, or debt) within two trading days of receipt, up to the outstanding balance.
-
Monitoring Fee Adds ~17.65% at 150 Days
If the note remains outstanding at the 150-day mark, a monitoring fee equal to the outstanding balance divided by 0.85 minus the outstanding balance (approximately 17.65%) is automatically added to the balance.
Analysis · NMAD · Life Sciences
On September 28, 2026, Nomad Power Solutions entered a $6.57 million secured note purchase agreement with Streeterville Capital, receiving $6.0 million in gross proceeds after a $540,000 original issue discount and $30,000 in transaction expenses. The note carries a 9% interest rate, matures in 12 months, and is secured by a first-position lien on substantially all company assets, including equity interests in its subsidiaries. The lender can redeem up to $800,000 per month beginning at the six-month mark, and the company must prepay 25% of any future financing proceeds. Against the backdrop of the going-concern warning disclosed in the August 10-Q and the $3.98 million warrant cash settlement obligation, this financing provides near-term liquidity but at a steep cost — the monitoring fee alone could add roughly 17.65% to the outstanding balance if the note remains unpaid at 150 days, and the security interest gives the lender a claim on all assets in a default scenario.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NMAD was trading at $3.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.2M. The 52-week trading range was $2.36 to $8.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.